Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib Maintenance Therapy in PTCL
NCT07414758Phase 3Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Feb 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Shanghai General Hospital. Started Feb 2026; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07414758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414758.